Assessment of the local clonal spread of Streptococcus pneumoniae serotype 12F caused invasive pneumococcal diseases among children and adults

Nakanishi, Noriko; Yonezawa, Takeshi; Tanaka, Shinobu; Shirouzu, Yuki; Naito, Yoshiro; Ozaki, Akemi; Hama, Natsuki; Ijichi, Akihiro; Iwamoto, Tomotada; Nomoto, Ryohei

doi:10.1016/j.jiph.2019.05.019

Cited by 9 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PPV23-unique serotypes accounted for 33.3% of S. pneumoniae isolates in our study, of which the most common serotype was 12F (16.4%); recent outbreaks of 12F have been reported in Japan and worldwide (Ubukata et al, 2018;Ladhani et al, 2018;Ohkusu et al, 2019;Nakanishi et al, 2019;Rokney et al, 2018). The mean age of patients presenting with IPD caused by serotype 12F was 63.8 years old, which was relatively young compared with IPD caused by other serotypes and is aligned with the previously reported relative increase of 12F isolates in IPD patients aged <65 years (Shimbashi et al, 2019).…”

Section: Discussionmentioning

confidence: 50%

Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae associated with invasive pneumococcal disease among adults in Japan

Yanagihara

Kosai

Mikamo

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

This study evaluated the serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae isolates from adults (aged !20 years) with invasive pneumococcal disease (IPD) in Japan. Methods: This prospective observational study was conducted in 49 participating Japanese hospitals. S. pneumoniae isolates were serotyped and tested for antimicrobial susceptibility at a central laboratory. Information regarding patient characteristics, underlying disease, IPD clinical syndromes, and treatment was collected through medical chart review. Results: The final analysis included 177 patients enrolled from 45 hospitals between September 2016 and April 2018 (bacteraemic pneumonia, 110; bacteraemia without identified focus, 29; meningitis, 19). Most patients (70.1%) were aged !65 years and most had underlying disease (79.1%). The proportion of isolates from serotypes contained in the pneumococcal polysaccharide vaccine (PPV) 23 was 61.0%, while those in the pneumococcal conjugate vaccine (PCV) 7 and PCV13 were 2.8% and 28.2%, respectively. Non-vaccine serotypes accounted for 37.9% of all isolates and 50.8% of isolates from immunosuppressed patients. Serotype 12F was the most common vaccine serotype, followed by serotype 3. Conclusions: The continued disease burden of IPD in adults in Japan warrants improved vaccination rates and development of next-generation vaccines that include serotypes not currently covered.

show abstract

Section: Discussionmentioning

confidence: 50%

Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae associated with invasive pneumococcal disease among adults in Japan

Yanagihara

Kosai

Mikamo

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…In children, before the introduction of PCV7 in 2010, the prevalence rates of PCV7 and PCV13 serotypes were as follows: 70.6%–81.3% among IPDs [ 22 , 27–31 ] and 62.7%–68.4% among all other PDs [ 24 , 32 , 33 ] for PCV7 serotypes; and 83.1% among IPDs [ 28–30 ] and 80.4%–86.0% among all other PDs [ 24 , 32 ] for PCV13 serotypes. After the switch from PCV7 to PCV13 in 2013, PCV7 and PCV13 type serotypes became less prevalent (0% among IPDs [ 21 , 34 , 35 ] and nearly 0% among all other PDs, including acute otitis media [ 36–38 ] for PCV7 serotypes; 4.0%–5.0% among IPDs [ 21 , 34 ] and 19.1% among all other PDs [ 36–38 ] for PCV13 serotypes).…”

Section: Resultsmentioning

confidence: 99%

Burden of illness associated with pneumococcal infections in Japan - a targeted literature review

Igarashi

Ueyama²,

Idehara³

et al. 2021

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

Introduction: Pneumococcal diseases (PDs) are among the leading causes of mortality and morbidity worldwide. However, the evidence on epidemiology, health economic, and patient-reported outcomes has not been systematically reviewed and published in Japan. This study aimed to assess the burden, treatment adherence and compliance, and serotype distribution associated with PDs in Japan. Method: One hundred and eight studies were identified between January 2005 and June 2020. The identified studies were mostly regional and with a limited scale, clinical settings, and populations. Results: In 2013–2017, invasive PD incidence rates were 4.98–9.47/100,000 in <4-year-olds, 0.36/100,000 in 5–14-year-olds, 0.46/100,000 in 15–64-year-olds, and 1.50–5.38/100,000 in the elderly. The incidence of invasive PDs in children decreased from 24.6/100,000 in 2008 to 10.7/100,000 in 2013 after the introduction of PCV7 and further declined to 10.3/100,000 in 2014 after PCV13 was introduced. From 2014, the prevalence of PCV13 serotypes decreased across all age groups along with a decrease of PPV23 serotypes, but an increase of PPV23 serotypes not included in PCV13 among adults and the elderly. No study reported health-related quality-of-life data for PDs. In children, direct costs were 340,905–405,978 JPY (3,099–3,691 USD) per pneumococcal bacteraemia, 767,447–848,255 JPY (6,977–7,711 USD) per pneumococcal meningitis, and 79,000 JPY (718 USD) per pneumococcal acute otitis media episodes. In adults and the elderly, the direct cost of pneumococcal pneumonia was 348,280–389,630 JPY (3,166–3,542 USD). The average hospital stay length was 7.2–31.9 days in children, 9.0 days in adults and 9.0–28.7 days in adults and the elderly. Conclusions: The epidemiological burden of PDs remains high in Japan, especially among children and the elderly with invasive PDs accounting for a very small proportion of all PDs. A significant impact of the PCV13 vaccine program was reported, while the PPV23’s impact remains unclear. A substantial decrease in quality-adjusted life years in adults and the elderly and a high economic burden may exist.

show abstract

“…To date, 3 studies have demonstrated outbreaks of serotype 12F-CC4846 in Japan during 2016-2018 (36)(37)(38). Of the 3 outbreaks, 2 can be attributed to ST4846 isolates that occurred in the Chiba Prefecture in the Kanto region and in the Yamagata Prefecture in the Tohoku region.…”

Section: Discussionmentioning

confidence: 99%

Streptococcus pneumoniae Serotype 12F-CC4846 and Invasive Pneumococcal Disease after Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Japan, 2015–2017

Nakano¹,

Fujisawa²,

Ito³

et al. 2020

Emerg. Infect. Dis.

View full text Add to dashboard Cite

To prevent invasive pneumococcal disease (IPD), pneumococcal conjugate vaccines (PCVs) have been implemented in many countries; however, many cases of IPD still occur and can be attributable to nonvaccine serotypes of Streptococcus pneumoniae . In Japan, the number of IPD cases attributable to serotype 12F increased from 4.4% in 2015 to 24.6% in 2017 after 13-valent PCV was introduced. To clarify the associated genetic characteristics, we conducted whole-genome sequencing of 75 serotype 12F isolates. We identified 2 sequence types (STs) among the isolates: ST4846, which was the major type, and ST6945. Bayesian analysis suggested that these types diverged in »1942. Among serotype 12F-ST4846, we identified a major cluster, PC-JP12F, whose time of most recent common ancestor was estimated to be »2012. A phylogeographic analysis demonstrated that PC-JP12F isolates spread from the Kanto region, the most populated region in Japan, to other local regions.

show abstract

Assessment of the local clonal spread of Streptococcus pneumoniae serotype 12F caused invasive pneumococcal diseases among children and adults

Cited by 9 publications

References 21 publications

Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae associated with invasive pneumococcal disease among adults in Japan

Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae associated with invasive pneumococcal disease among adults in Japan

Burden of illness associated with pneumococcal infections in Japan - a targeted literature review

Streptococcus pneumoniae Serotype 12F-CC4846 and Invasive Pneumococcal Disease after Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Japan, 2015–2017

Contact Info

Product

Resources

About